Rhythm Pharmaceuticals, Inc. Forecast, price target & analysts
Rhythm Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
Rhythm Pharmaceuticals, Inc. Classifications & Recommendation:
Rhythm Pharmaceuticals, Inc. Price Target
| Target Price | $117.30 |
| Price | $99.41 |
| Potential |
18.00%
register free of charge
|
| Number of Estimates | 16 |
|
16 Analysts have issued a price target Rhythm Pharmaceuticals, Inc. 2026 .
The average Rhythm Pharmaceuticals, Inc. target price is $117.30.
This is
18.00%
register free of charge
$149.10
49.98%
register free of charge
$95.95
3.48%
register free of charge
|
|
| A rating was issued by 20 analysts: 19 Analysts recommend Rhythm Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Rhythm Pharmaceuticals, Inc. stock has an average upside potential 2026 of
18.00%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 130.13 | 190.11 |
| 68.06% | 46.09% | |
| EBITDA Margin | -202.83% | -94.16% |
| 13.99% | 53.58% | |
| Net Margin | -203.31% | -107.53% |
| 14.76% | 47.11% |
16 Analysts have issued a sales forecast Rhythm Pharmaceuticals, Inc. 2025 . The average Rhythm Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Rhythm Pharmaceuticals, Inc. EBITDA forecast 2025. The average Rhythm Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
16 Rhythm Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Rhythm Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -4.34 | -3.07 |
| 35.63% | 29.26% | |
| P/E | negative | |
| EV/Sales | 33.28 |
16 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast for earnings per share. The average Rhythm Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Rhythm Pharmaceuticals, Inc....
Current Rhythm Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Nov 10 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Nov 07 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Nov 04 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Oct 17 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Oct 16 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 29 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Sep 25 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Nov 10 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Nov 07 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Nov 04 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Oct 17 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Oct 16 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 29 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Sep 25 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
